Akums Drugs and Pharmaceuticals Ltd.
NSE: AKUMS · Pharmaceuticals
Snapshot
Unlock Akums Drugs and Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Akums Drugs and Pharmaceuticals Limited is a prominent Indian pharmaceutical company specialising in contract development and manufacturing (CDMO). The company produces a diverse range of products including formulations, active pharmaceutical ingredients (APIs), nutraceuticals, and cosmetics across various therapeutic segments.
Business Model
The company operates primarily as a contract manufacturer, providing end-to-end pharmaceutical solutions from formulation development to commercial-scale production for various clients. It generates revenue through the sale of branded formulations, APIs, and healthcare products across domestic and international markets.
- Incorporation Year:2004
Growth Outlook
Growth is driven by the expansion of its CDMO capabilities and a broad portfolio spanning diverse therapeutic areas like cardiology, gynaecology, and dermatology. The company continues to leverage its manufacturing infrastructure to cater to the increasing demand for outsourced pharmaceutical production.
Key Risks
- Regulatory Compliance. The company is subject to stringent quality and safety regulations from health authorities, where non-compliance could lead to manufacturing suspensions.
- Client Concentration. As a contract manufacturer, the company's revenue is heavily dependent on the commercial success and outsourcing strategies of its pharmaceutical client base.
- Input Cost Volatility. Fluctuations in the prices of raw materials and active pharmaceutical ingredients can significantly impact operating margins.
- Competitive Intensity. The pharmaceutical manufacturing sector is highly fragmented, leading to intense price competition and pressure on contract manufacturing margins.
Start your research today
Unlock AI insights, financials, peers and live data on Akums Drugs and Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹4,502 Cr
TTM · consolidated
NET PROFIT
₹293 Cr
TTM · consolidated
EPS
₹19.05
TTM · consolidated
RETURN ON EQUITY
9.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
13.8%
TTM · consolidated
P/E
40.2x
Q1 FY27 · consolidated
EV/EBITDA
16.8x
Q1 FY27 · consolidated
EBITDA MARGIN
15.6%
TTM · consolidated
NET PROFIT MARGIN
8.7%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Akums Drugs and Pharmaceuticals Ltd.AKUMS | ₹12,052 Cr | 40.20 | 16.77 | 9.2% | 15.6% | 9.2% | 13.8% | +64.4% |
Corona RemediesCORONA | ₹12,844 Cr | 64.54 | 39.52 | — | 22.2% | 26.6% | 31.7% | — |
Blue Jet Healthcare Ltd.BLUEJET | ₹10,785 Cr | 42.05 | 30.92 | -27.5% | 39.2% | 18.8% | 25.0% | -19.6% |
Strides Pharma Science LimitedSTAR | ₹9,767 Cr | 15.92 | 10.37 | 7.3% | 21.7% | 22.4% | 24.5% | +20.0% |
Sanofi Consumer Healthcare India Ltd.SANOFICONR | ₹9,677 Cr | 36.38 | 24.67 | 31.2% | 39.2% | 87.9% | 107.5% | -19.4% |
Procter & Gamble Health LimitedPGHL | ₹9,395 Cr | 26.33 | 19.08 | 44.9% | 33.7% | 67.2% | 84.2% | -12.4% |
As of Q1 FY27
Financials
Akums Drugs and Pharmaceuticals Ltd.
NSE: AKUMS · Pharmaceuticals
Snapshot
Unlock Akums Drugs and Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Akums Drugs and Pharmaceuticals Limited is a prominent Indian pharmaceutical company specialising in contract development and manufacturing (CDMO). The company produces a diverse range of products including formulations, active pharmaceutical ingredients (APIs), nutraceuticals, and cosmetics across various therapeutic segments.
Business Model
The company operates primarily as a contract manufacturer, providing end-to-end pharmaceutical solutions from formulation development to commercial-scale production for various clients. It generates revenue through the sale of branded formulations, APIs, and healthcare products across domestic and international markets.
- Incorporation Year:2004
Growth Outlook
Growth is driven by the expansion of its CDMO capabilities and a broad portfolio spanning diverse therapeutic areas like cardiology, gynaecology, and dermatology. The company continues to leverage its manufacturing infrastructure to cater to the increasing demand for outsourced pharmaceutical production.
Key Risks
- Regulatory Compliance. The company is subject to stringent quality and safety regulations from health authorities, where non-compliance could lead to manufacturing suspensions.
- Client Concentration. As a contract manufacturer, the company's revenue is heavily dependent on the commercial success and outsourcing strategies of its pharmaceutical client base.
- Input Cost Volatility. Fluctuations in the prices of raw materials and active pharmaceutical ingredients can significantly impact operating margins.
- Competitive Intensity. The pharmaceutical manufacturing sector is highly fragmented, leading to intense price competition and pressure on contract manufacturing margins.
Start your research today
Unlock AI insights, financials, peers and live data on Akums Drugs and Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹4,502 Cr
TTM · consolidated
NET PROFIT
₹293 Cr
TTM · consolidated
EPS
₹19.05
TTM · consolidated
RETURN ON EQUITY
9.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
13.8%
TTM · consolidated
P/E
40.2x
Q1 FY27 · consolidated
EV/EBITDA
16.8x
Q1 FY27 · consolidated
EBITDA MARGIN
15.6%
TTM · consolidated
NET PROFIT MARGIN
8.7%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27